Tory Tablets 60,90,120mg

Composition

Tory 60 Tablet: Each film coated tablet contains Etoricoxib 60mg.

Tory 90 Tablet: Each film coated tablet contains Etoricoxib 90mg.

Tory 120 Tablet: Each film coated tablet contains Etoricoxib 120mg.

Pharmacology

Tory (Etoricoxib) is a Non-Steroidol Anti-inflammatory Drug (NSAID) that exhibits anti-inflammatory, analgesic and antipyretic activities. It is a potent, orally active, highly selective cyclooxygenase-2 (COX-2) inhibitor within and above the clinical dose range. COX-2 has been shown to be primarily responsible for the synthesis of prostanoid mediators of pain, inflammation and fever. Selectivee inhibition of COX-2 by Etoricoxib decreases these clinical signs and symptoms with decreased GI toxicity and without effects on platelet function.

Etoricoxib Tablet

Class: NSAID

Manufacturer: Square Pharmaceuticals Kenya EPZ Ltd, Athi River, Machakos, Kenya

Dosage Form: Tablet

Similar Brands: Etoday (Etoricoxib 60/90/120mg)

Uses:

Tory (Etoricoxib) is indicated for relief of pain and inflammation in;

  • Osteoarthritis
  • Rheumatoid arthritis
  • Other chronic musculoskeletal disorders
  • Acute gout
  • Dysmenorrhoea &
  • Following dental surgery

Dosage:

Adult and adolescent over 16 years:

Osteoarthritis, chronic musculoskeletal disorders & dysmenorrhoea: 60mg once daily

Rheumatoid arthritis: 90mg once daily.

Pain following dental surgery & acute gout: 120mg once daily

Safety and effectiveness of etoricoxib in paediatric patients have not been established.

Side Effects:

Dry mouth, taste disturbance, mouth ulcers, flatulence, constipation, appetite and weight changes, chest pain, fatigue, paresthesia, influenza-like syndrome & myalgia.

Warnings & Precautions:

Caution should be used when initiating, treatment with it in patients with considerable dehydration. It is advisable to rehydrate patients prior to starting therapy with it. The possibility of fluid retention, oedema or hypertension should be taken into consideration when it is used in patients with pre-existing oedema, hypertension, or heart failure. Independent of treatment, patients with a prior history of GI perforation, ulcers and bleeding (PUB) and patients greater than 65 years of age are known to be at a higher risk for a PUB.

A patient with symptoms and/or signs suggesting liver dysfunction, or in whom an abnormal liver function test has occurred, should be evaluated for persistently abnormal liver function tests. If persistently abnormal live function tests (three times the upper limit of normal) are detected. It should be discontinued. It should be used with caution in patients who have previously experienced acute asthmatic attacks, uritcaria, or rhinitis, which were precipitated by salicylates or non-selective cyclooxygenase inhibitors. It may mask fever, which is a sign of infection. The physician should be aware of this when using it in patients being treated for infection.

Pregnancy & Lactation:

As with other drugs known to inhibit prostaglandin synthesis, use of it should be avoided in late pregnancy because it may cause premature closure of the ductus arteriosus. It should be used during the first two trimesters of pregnancy only if the potential benefit justifies the potential risk of the foetus. It is not known whether this drug is excreted in human milk

Drug Interactions:

Oral anticoagulants, diuretics and ACE inhibitors, acetylsalicylic acid, cyclosporine and tacrolimus, lithium, methotrexate, oral contraceptives, prednisone/prednisolone, digoxin, drugs metabolized by sulfotranferases (ethyl estradiol), drugs metabolized by CYP isoenyzme, ketoconazole, rifampicin, and antacids have interaction with etoricoxib.

Contraindications:

Etoricoxib is contraindicated to patients with known hypersensitivity to Etoricoxib, patients with active peptic ulceration or gastro-intestinal (GI) bleeding, patients who have developed signs of asthma, acute rhinitis, nasal polyps, angioneurotic oedema or urticaria following the administration of acetylsalicylic acid or other Non-Steroidol Anti-inflammatory Drug (NSAID), patient having inflammatory bowel disease, severe congestive heart failure, to children and adolescents under 16 years of age.

In patients with advanced renal disease, treatment with it is not recommended. Clinical experience in patients with estimated creatinine clearance of <30 ml/min is very limited. If therapy with it must be initiated in such patients, close monitoring of the patient’s renal function is advisable.

Price: Ksh 950

Notes:

Pack size: 30s